TRUMP: Ozempic Will Soon be $150 in the US! Meet the Reporter Who Made Him Say It!
GET ACCESS TO OBESITY CARE AND MEDS AND SUPPORT OTP:
https://lddy.no/1ndi6
USE CODE: OTP25
VISIT ALL OUR LINKS:
https://linktr.ee/manonthemounjaro Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
--------
29:33
--------
29:33
Wegovy and Ozempic Users: FDA's Scathing Report on Major Novo Factory
Visit our Sponsors and check out EXCLUSIVE OTP Savings!
www.OTPLinks.com
www.tryshed.com (use code OTP25 to save 25%) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
--------
27:44
--------
27:44
Retatrutide News That Could Change Everything for GLP-1 Compounds
SUPPORT OUR WORK:
OTPLinks.com
💉 Story 1 — Fractyl Health’s One-and-Done Gene Therapy for Obesity
Fractyl Health just dropped preclinical results showing their GLP-1 + GIP gene therapy candidate RJVA-002 produced almost 30% weight loss in mice after a single dose. I sat down with Dr. Harith Rajagopalan, CEO of Fractyl Health, to talk about how this new Rejuva® platform works, what it means for people living with obesity and type 2 diabetes, and why gene therapy might be the future of metabolic care.
🏛️ Story 2 — Medicare Coverage for GLP-1s? Dr. Oz Drops a Hint
At the Aspen Institute, CMS Administrator Dr. Mehmet Oz said even a comment on GLP-1 coverage would be “market moving.” We break down what that means, why the Trump administration shelved a rule that would’ve added obesity meds to Medicare coverage, and how that decision might now be a bargaining chip to lower drug prices in exchange for tougher enforcement on compounding.
⚖️ Story 3 — The Retatrutide Ruling and the Future of Compounded Access
A federal judge ruled the FDA acted “arbitrarily and capriciously” when it rejected Lilly’s bid to classify retatrutide as a biologic. That may sound technical, but if the FDA changes its stance, it could have huge implications for tirzepatide (Zepbound, Mounjaro) and semaglutide (Wegovy, Ozempic)—especially when it comes to compounding and patient access. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
--------
40:26
--------
40:26
Sobriety Meets Weight Loss: The Ethan Suplee Interview
View All My Links:
https://www.OTPLinks.com
Join Ethan's Live:
2way.tv/ethansuplee Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
--------
38:01
--------
38:01
Mounjaro Hair Loss + NFL Lineman Discovers Power in Personalized Medicine
otplinks.com
stallybrand.com (code OTP10) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
Listen to On The Pen With Dave Knapp, Nothing much happens: bedtime stories to help you sleep and many other podcasts from around the world with the radio.net app
USA